"Alexa, let's walk to the kitchen" – combined technologies to enhance mobility for individuals with severe lower body impairments, as well as growing global aging population
TORONTO and BOSTON, Aug. 8, 2017 /CNW/ -- Bionik Laboratories Corp. (OTCQX:BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has integrated Amazon's Echo ("Echo") technology and Alexa Voice Service ("Alexa") into its ARKE™ lower body exoskeleton.
The ARKE™ exoskeleton utilizes Bionik's proprietary transmission and actuation system, making it one of the most powerful robotic devices compared to similar systems. It will now include device control, utilizing multiple sensors located throughout the device in combination with Alexa. Users will be able to activate different activity modes, such as Standing and Walking, by saying "Alexa, I'm ready to stand" or "Alexa, I'm ready to walk."
Most movements – including walking and standing – are initiated by the upper body. As such, sensors in the feet, angle sensors in the joints, and inertial measurement units feel how the body weight is distributed and, combined with upper body information and movements, allow you to take a step. Utilizing artificial intelligence (AI) to translate information from all this sensor information intelligently activates the ARKE™ for those paralyzed from the waist down, as it mimics movements that would generally allow an able person to take steps.
"We are excited to complete the integration of Amazon's Echo and Alexa into our ARKE exoskeleton, combining the power of Amazon's voice-activated technologies with our powerful assistive robotic solutions for the next evolution in treating consumer immobility," said Michal Prywata, co-founder, Chief Operating Officer and Director of Bionik. "In building ARKE, we had one goal in mind – to empower the user to take back their mobility and regain the ability to complete tasks that the rest of us deem normal, like walking to the refrigerator or going to get the mail. This pairing of our robotic technologies with the power of Amazon's Alexa further pushes the boundaries of what technology can do within the home healthcare industry, and we believe we will help many impaired individuals regain the mobility they once lost."
Bionik's current ARKE™ product is in clinical development and aimed toward use by those who have suffered a spinal cord injury or are otherwise severely impaired in their lower body due to stroke, traumatic brain injury, or some other incident. Further opportunity also exists within the aging population, approaching a billion people globally, who rely on unstable walkers or other wheeled devices for mobility.
Following its recent partnership with Wistron Corporation, the Company is seeking to produce a home-type exoskeleton product with a lower price point that is more accessible to the average consumer. The goal will be to make these devices financeable, so the user pays a smaller monthly fee than normal cost of care – building a ramp, paying for nurses, wheelchair rental – would be for someone with a mobility injury.
"The continued evolution of our ARKE exoskeleton is important for our Company, as the market for assistive mobility products continues to grow at a rapid pace across the globe," said Peter Bloch, Chief Executive Officer and Chairman of the Board of Bionik. "Aside from the large number of citizens who have suffered injury, the global population is also aging rapidly, and those citizens will be in need of a home-based assistive product that can truly provide them the mobility that a wheelchair, cane, or crutches currently can't. We will continue to seek out partnerships and technological advancements that will enable us to serve that population on a mass consumer scale."
The Centers for Disease Control and Prevention estimates that nearly nine million people in the United States have a mobility challenge that requires assistive products – an estimated 2.2 million depend on a wheelchair, while an estimated 6.5 million use a cane, walker, or crutches. Globally, that market expands significantly, with The Wheelchair Foundation estimating that almost 132 million people globally have a physical disability and require a wheelchair for mobility.
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development. The InMotion Systems — the InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion AnkleBot™ — are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is designed to continually adapt to a patient's ability and provide real-time feedback to the physiotherapist.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
SOURCE Bionik Laboratories Corp.
For further information: Matt Bretzius, FischTank Marketing and PR, [email protected]; Investor Relations contact: Amato and Partners, LLC, Investor Relations Counsel, [email protected], http://www.bioniklabs.com